has erenumab been approved by nice?
532029
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
1234921
EVISTA is approved by the U.S. Food and Drug Administration (FDA) for the treatment and prevention of osteoporosis in postmenopausal women. EVISTA is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.
1331860
Summary. Idarucizumab is the first agent to be licensed in the UK that reverses the anticoagulant effect of a non‑vitamin K antagonist oral anticoagulant (NOAC). ... Regulatory status: Idarucizumab (Praxbind, Boehringer Ingelheim Limited) was launched in the UK in December 2015.
1364957
Four anti-CGRP monoclonal antibodies are currently in development for use in the prevention of episodic and chronic migraines: eptinezumab, erenumab, fremanezumab, and galcanezumab. They have not yet been approved in any country. Phase II and phase III trial results are available for all four drugs.
1207799
The recommendation from NICE today will make nivolumab available immediately to NHS patients in England via the CDF. Nivolumab will be reimbursed as adjuvant treatment after surgery, for melanoma patients with involvement of lymph nodes or metastatic (advanced) disease who have undergone complete resection.
300905
Whatever the reason, we have some good news for those of you taking the expensive cholesterol medication Zetia! As of December 12th, 2016 the FDA approved ezetimibe, a less expensive generic to Zetia, and it is in pharmacies now.
1068758
It's been a little over a year since U.S. regulators approved Genentech's Ocrevus (ocrelizumab) as the first treatment for both relapsing and progressive forms of multiple sclerosis (MS) — a disabling neurological disease now believed to affect nearly one million Americans.
936160
Both Xgeva (chemical name: denosumab) and Zometa (chemical name: zoledronic acid) are approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of bone problems (such as breaking a bone) and bone pain caused by advanced-stage cancer that has spread to the bones.
795343
Three new treatments for type 2 diabetes have been recommended by NICE, for patients who cannot use metformin, sulfonylurea or pioglitazone. The treatments are also suitable for patients who are not controlling their blood glucose levels with diet and exercise alone, to manage their condition.
776994
['reslizumab (Cinqair)', 'mepolizumab (Nucala)', 'omalizumab (Xolair)', 'benralizumab (Fasenra)']
688637
Aimovig™ (erenumab) is an injectable human monoclonal antibody (mAb) co-developed by pharmaceutical companies Novartis and Amgen. Formerly known as AMG 334, Aimovig belongs to a class of drugs known as selective calcitonin gene-related peptide (CGRP) antagonists, used for the treatment of acute migraine attacks.
529881
Rezum received NICE approval in the UK on 21 August 2018. This means it is now a recommended treatment for BPH on the NHS.
124160
['trastuzumab (Herceptin)', 'pertuzumab (Perjeta)', 'bevacizumab (Avastin)', 'rituximab (Mabthera)']
803559
Xtandi Patient Assistance Program Enzalutamide has been approved for use by Health Canada and has been recommended for funding by the pan-Canadian Oncology Drug Review (pCODR) for both indications.
1234046
ASEA is supposed to improve immune function and promote overall health. These claims by the company may or may not be supported, so do further research on your own before making a decision to take it as a supplement.
717992
['abatacept (Orencia)', 'rituximab (Rituxan)', 'tocilizumab (Actemra)', 'anakinra (Kineret)', 'adalimumab (Humira)', 'etanercept (Enbrel)', 'infliximab (Remicade)', 'certolizumab pegol (Cimzia)']
1383170
The FDA recently approved lifitegrast ophthalmic solution (Xiidra) to treat both the signs and symptoms of dry eye disease (DED) with an onset of action in as little as 2 weeks. It's the first approved drug in a new class called lymphocyte function-associated antigen 1 (LFA-1) antagonists.